OncoMatch/Clinical Trials/NCT03761108
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
Is NCT03761108 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Linvoseltamab for multiple myeloma.
Treatment: Linvoseltamab — The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can effectively treat cancer. The study is looking at several other research questions, including: * Side effects that may be experienced by people receiving linvoseltamab * How linvoseltamab works in the body * How much linvoseltamab is present in the blood * How linvoseltamab may work to treat cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: proteasome inhibitor
Progression on or after at least 3 lines of therapy, or intolerance of therapy, including a proteasome inhibitor, an Immunomodulatory agent (IMiD), and an anti-CD38 antibody
Must have received: immunomodulatory agent
Progression on or after at least 3 lines of therapy, or intolerance of therapy, including a proteasome inhibitor, an Immunomodulatory agent (IMiD), and an anti-CD38 antibody
Must have received: anti-CD38 antibody
Progression on or after at least 3 lines of therapy, or intolerance of therapy, including a proteasome inhibitor, an Immunomodulatory agent (IMiD), and an anti-CD38 antibody
Cannot have received: BCMA-directed immunotherapy (BCMA bispecific antibody, BiTE)
Exception: BCMA antibody-drug conjugates are not excluded and BCMA-directed CAR-T treatment is not excluded in Phase 2 Cohort 3
Prior treatment with BCMA-directed immunotherapies, including BCMA bispecific antibodies and BiTEs. Note: BCMA antibody-drug conjugates are not excluded and BCMA-directed CAR-T treatment is not excluded in Phase 2 Cohort 3.
Cannot have received: allogeneic stem cell transplant
History of allogeneic stem cell transplantation at any time
Cannot have received: autologous stem cell transplant
Exception: within 12 weeks of the start of study treatment
autologous stem cell transplantation within 12 weeks of the start of study treatment
Lab requirements
Cardiac function
Cardiac ejection fraction <40% by echocardiogram or MUGA excluded
Cardiac ejection fraction <40% by echocardiogram or multi-gated acquisition scan (MUGA)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sylvester Comprehensive Cancer Center · Miami, Florida
- Moffitt Cancer Center - McKinley Drive · Tampa, Florida
- Emory University Hospital · Atlanta, Georgia
- Indiana University_Michigan Street · Indianapolis, Indiana
- Norton Cancer Institute · Louisville, Kentucky
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify